Tag Archives | melanoma market research

Zelboraf (vemurafenib) approved in metastatic melanoma

Last week the hot news was the anticipated FDA approval of vemurafenib (Zelboraf™) in metastatic melanoma for patients with BRAF V600E mutations. Sally Church on Pharma Strategy Blog has written extensively about new products in development for metastatic melanoma.  As Sally notes in her recent blog post discussing the Zelboraf™ approval: “the good news is that […]

Continue Reading

Understanding why melanoma patients develop resistance to PLX4032

Targeted therapies for metastatic melanoma such as PLX4032 (vemurafenib) have shown dramatic effects in patients.  However, resistance to BRAF inhibitors such as PLX4032 soon develops. The result is a need to understand how resistance occurs due to cross talk and how to overcome this through a rational drug combination strategy. Sally Church on Pharma Strategy […]

Continue Reading

Whole-Exome Sequencing of Melanoma leads to discovery that Glutamate Antagonists limit tumor growth

At the recent Association of Health Care Journalists (AHCJ) annual meeting in Philadelphia that Pieter Droppert attended, one of the keynote speakers was Francis Collins, Director of the National Institutes of Health (NIH). In his presentation he drew the attention of the assembled audience to exciting new research supported by the NIH on whole-exome sequencing […]

Continue Reading